International Multicentric Study ARON-1

Recruiting now

Conditions studied: Metastatic Renal Cell Carcinoma (mRCC)

In brief

The ARON-1 Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of immuno-combinations in patients with metastatic RCC. Two Supplementary Studies (ARON-1α and ARON-1β) have been designed. The ARON-1α Supplementary Study has been designed to investigate for the presence of genomic signatures from tumor samples of patients treated with first-line immuno-combinations for advanced RCC. The ARON-1β Supplementary Study has been designed to charaterize the immune cell populations and assess their relationship with the clinical outcome of mRCC patients treated with first-line immuno-combinations

Key facts

Study ID

NCT05287464

Run by

Hospital of Macerata

People needed

1220

Starts

2022-03-10

Expected to finish

2027-09-30

Last updated by the study team

2025-11-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients aged >18y
• Cytological or Histologically confirmed diagnosis of clear cell or non-clear cell RCC
• Histologically or radiologically confirmed diagnosis of metastatic disease
• First-line treatment with nivolumab plus ipilimumab or nivolumab plus cabozantinib or pembrolizumab plus axitinib or pembrolizumab plus lenvatinib or avelumab plus axitinib or atezolizumab plus bevacizumab

You may not qualify if…

• Patients without histologically confirmed diagnosis of RCC
• Patients without histologically or radiologically confirmed metastatic disease
• Patients treated with immuno-combinations not included in the list reported in the Inclusion Criteria Section

Where it is running

• Ospedale di Macerata, UOC Oncologia — Province of Macerata, Macerata, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.